Synlett 2013; 24(20): 2695-2700
DOI: 10.1055/s-0033-1340010
letter
© Georg Thieme Verlag Stuttgart · New York

Rapid and Selective in situ Reduction of Pyridine-N-oxides with Tetra­hydroxydiboron

Allyn T. Londregan*
CVMED Medicinal Chemistry, Pfizer Inc., Eastern Point Road, Groton, CT 06340, USA   Fax: +1(860)7154695   eMail: allyn.t.londregan@pfizer.com
,
David W. Piotrowski
CVMED Medicinal Chemistry, Pfizer Inc., Eastern Point Road, Groton, CT 06340, USA   Fax: +1(860)7154695   eMail: allyn.t.londregan@pfizer.com
,
Jun Xiao
CVMED Medicinal Chemistry, Pfizer Inc., Eastern Point Road, Groton, CT 06340, USA   Fax: +1(860)7154695   eMail: allyn.t.londregan@pfizer.com
› Institutsangaben
Weitere Informationen

Publikationsverlauf

Received: 24. Juli 2013

Accepted after revision: 16. September 2013

Publikationsdatum:
05. November 2013 (online)


Preview

Abstract

Pyridine-N-oxides are often used as reactive precursors in the syntheses of substituted pyridines. Isolation and subsequent reduction of the associated pyridine-N-oxide intermediates can be challenging. We have discovered that tetrahydroxydiboron functions as a mild, versatile, and remarkably selective reducing agent for pyridine-N-oxides and may be used in an in situ fashion, thus ­obviating the isolation of N-oxide-containing intermediates

Supporting Information